**PATENT** 

### IN THE UNITED STATES PATENT AND TRADMARK OFFICE

FRADEMA plicants: Kawai, et al.

Serial No.: 10/616,628

Filed: July 10, 2003

JAN 17 2006

Patent No.: 6,849,757 62

Issued: Feb. 1, 2005

Title: Antiangiogenic Drug to Treat Cancer,

Arthritis and Retinopathy

Case No.: 6357USD1

Group Art No.: 1625

Examiner: Paul J. Killos

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as

first class mail in an envelope addressed to the:

Certificate of Correction Branch Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Date

#### REQUEST FOR CERTIFICATE OF CORRECTION

**Certificate of Correction Branch Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

Certificate JAN 2 0 2006

Dear Sir:

of Correction

Upon review of the final printed copies of the above-identified patent and comparison with the application file, Applicants have identified errors in the patent as printed. Accordingly, Applicants request that a Certificate of Correction be issued pursuant to 35 U.S.C. 254 for this patent as set forth on the attached Form PTO 1050, identifying errors by column and line from the patent. Since the errors appear to be due to the fault of the Patent and Trademark Office, Applicants believe no fee is due.

ABBOTT LABORATORIES

Customer Number 23492

Telephone: (847) 935-7956 Facsimile: (847) 938-2623 Respectfully submitted,

Kawai, et al.

Johanna M. Corbin

Registration No. 51,582 Attorney for Applicants



#### IN THE UNITED STATES PATENT AND TRADMARK OFFICE

Spplicants: Kawai, et al.

Serial No.: 10/616,628

Filed: July 10, 2003

Patent No.: 6,849,757 B2\_\_\_\_

Issued: Feb. 1, 2005

Title: Antiangiogenic Drug to Treat Cancer,

Arthritis and Retinopathy

Case No.: 6357USD1

Group Art No.:

1625

Examiner: Paul J. Killos

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Certificate of Correction Branch

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Date of Deposit:

LANLANIS

Date

16/2006

hae Y Lewis I

#### TRANSMITTAL LETTER

Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith for the patent application identified above entitled Antiangiogenic Drug to Treat Cancer, Arthritis and Retinopathy are the following:

- 1. Request for Certificate of Correction;
- 2. Certificate of Correction (PTO 1050), in duplicate; and
- 3. Return Receipt Postcard

The Commissioner is herby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,

Kawai, et al.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-7956

Facsimile: (847) 938-2623

ohanna M. Corbin

Registration No. 51,582 Attorney for Applicants Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION Page 1 of 1 :6849757 B2 PATENT NO. APPLICATION NO.: 10/616.628 : July 10, 2003 **ISSUE DATE** INVENTOR(S) : Megumi Kawai, et al. It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below: Col. 38, line 32 replace "carboxylic" with --carboxylate--.

MAILING ADDRESS OF SENDER (Please do not use customer number below): 6849757

Robert DeBerardine Abbott Laboratories Dept. 377 AP6A-1 100 Abbott Park Road Abbott Park, IL 60064-6008

2

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. :6849757 B2-

Page <u>1</u> of <u>1</u>

AFFLICATION NO.. 10

APPLICATION NO.: 10/616.628

**ISSUE DATE** 

: July 10, 2003

INVENTOR(S)

: Megumi Kawai, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 38, line 32 replace "carboxylic" with --carboxylate--.

MAILING ADDRESS OF SENDER (Please do not use customer number below): 6849757

Robert DeBerardine Abbott Laboratories Dept. 377 AP6A-1 100 Abbott Park Road Abbott Park, IL 60064-6008

2

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.